Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.65 – $1.89
Volume17,432
Market cap$1M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for SLXN.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for SLXN.
Recent news
Company coverage with links to the original publishers.
Silexion Therapeutics announced a 1-for-24 reverse share split effective November 11, 2026, to regain compliance with Nasdaq's minimum bid price requirement and support its clinical progress with SIL204 in locally advanced pancreatic cancer. The company dosed its first patient in the Phase 2/3 trial in September 2026.
Silexion Therapeutics announced the first patient has been successfully dosed in its Phase 2/3 clinical trial of SIL204, an RNAi therapy for locally advanced pancreatic cancer with KRAS mutations. The trial combines direct intratumoral EUS-guided delivery with subcutaneous dosing alongside standard chemotherapy. The study includes an initial safety cohort of ~18 patients followed by expansion to ~166 patients across Israel and Germany.
Silexion Therapeutics has initiated GMP clinical manufacturing of SIL204, its next-generation siRNA therapy targeting mutated KRAS in pancreatic cancer, in collaboration with CDMO Catalent at its Limoges, France facility. The company received approval from Tel Aviv Sourasky Medical Center's Helsinki Ethics Committee for its planned Phase 2/3 trial in locally advanced pancreatic cancer, following earlier approvals from the Israeli Ministry of Health and a clinical trial application submission to Germany's BfArM.
Silexion Therapeutics received formal written Scientific Advice from the German Federal Institute for Drugs and Medical Devices regarding its planned Phase 2/3 clinical trial for SIL204, a potential treatment for locally advanced pancreatic cancer. The guidance provides regulatory clarity and supports the company's planned trial initiation in Q2 2026.
Silexion Therapeutics reported strong preclinical results for SIL204, a potential cancer therapy targeting KRAS mutations, raised $9.5 million in financing, and remains on track to initiate Phase 2/3 clinical trials in the first half of 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.